Kidney drug study: how avacopan behaves in dialysis patients
NCT ID NCT06468826
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This completed Phase 1 study looked at how the drug avacopan is processed in 13 people with normal kidney function and those with end-stage renal disease requiring hemodialysis. Researchers measured drug levels in the blood and dialysis fluid after a single dose. The goal was to understand safety and how the body handles the drug, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avacopan (oral capsules)
What this could lead to
If successful, this study could help doctors understand how to dose avacopan safely in kidney dialysis patients.
What could go wrong
This is a very early, small study (13 people) focused on drug levels, not treatment effects. Results may not apply to broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.